DE3417857C2 - Nicht-liposomales pharmazeutisches Mittel - Google Patents
Nicht-liposomales pharmazeutisches MittelInfo
- Publication number
- DE3417857C2 DE3417857C2 DE3417857A DE3417857A DE3417857C2 DE 3417857 C2 DE3417857 C2 DE 3417857C2 DE 3417857 A DE3417857 A DE 3417857A DE 3417857 A DE3417857 A DE 3417857A DE 3417857 C2 DE3417857 C2 DE 3417857C2
- Authority
- DE
- Germany
- Prior art keywords
- coenzyme
- phospholipids
- administration
- ubiquinone
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008177 pharmaceutical agent Substances 0.000 title claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 36
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 36
- 150000003904 phospholipids Chemical class 0.000 claims description 34
- 229940067631 phospholipid Drugs 0.000 description 33
- 235000017471 coenzyme Q10 Nutrition 0.000 description 31
- 229940110767 coenzyme Q10 Drugs 0.000 description 22
- 239000000203 mixture Substances 0.000 description 12
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 9
- 239000008347 soybean phospholipid Substances 0.000 description 9
- -1 Diphosphoinositide Chemical compound 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000002381 Brain Hypoxia Diseases 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940035936 ubiquinone Drugs 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 230000000923 atherogenic effect Effects 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000496 anti-anoxic effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100421142 Mus musculus Selenon gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 241001080519 Zera Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1774/84A CH661438A5 (it) | 1984-04-09 | 1984-04-09 | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3417857A1 DE3417857A1 (de) | 1985-10-17 |
| DE3417857C2 true DE3417857C2 (de) | 1997-04-24 |
Family
ID=4218293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3417857A Expired - Lifetime DE3417857C2 (de) | 1984-04-09 | 1984-05-14 | Nicht-liposomales pharmazeutisches Mittel |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4684520A (ref) |
| JP (1) | JPS6133118A (ref) |
| CH (1) | CH661438A5 (ref) |
| DE (1) | DE3417857C2 (ref) |
| FR (1) | FR2562422B1 (ref) |
| GB (1) | GB2157171B (ref) |
| IT (1) | IT1201412B (ref) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH661443A5 (en) * | 1984-11-22 | 1987-07-31 | Seuref Ag | Pharmaceutical compositions having metabolic activity |
| JPH01305032A (ja) * | 1988-06-01 | 1989-12-08 | Sanwa Kagaku Kenkyusho Co Ltd | 機能後退性消耗疾患治療予防剤及び飲食、し好物 |
| JPH01305033A (ja) * | 1988-06-01 | 1989-12-08 | Sanwa Kagaku Kenkyusho Co Ltd | 循環改善剤及び循環改善機能性食品並びにし好品 |
| JPH02188523A (ja) * | 1989-01-13 | 1990-07-24 | M S C:Kk | 睡眠時無呼吸症治療薬 |
| US6461593B1 (en) * | 1992-02-19 | 2002-10-08 | Biomedical And Clinical Research | Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease |
| WO1994015595A1 (en) * | 1993-01-06 | 1994-07-21 | Jemo-Pharm A/S | Medium comprising a pharmacological/biological active substance |
| US6312703B1 (en) | 1998-02-06 | 2001-11-06 | Lecigel, Llc | Compressed lecithin preparations |
| US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6441050B1 (en) * | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
| KR100612398B1 (ko) * | 2000-11-14 | 2006-08-16 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | 포스페이트 유도체의 착체 |
| AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| AU2002317053B2 (en) * | 2001-07-27 | 2004-08-05 | Vital Health Sciences Pty Ltd | Dermal therapy using phosphate derivatives of electron transfer agents |
| AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
| BR0215102A (pt) * | 2001-12-13 | 2004-11-03 | Vital Health Sciences Pty Ltd | Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação |
| JP2003261456A (ja) * | 2002-03-08 | 2003-09-16 | Howaizu:Kk | 脳の老化予防剤 |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| BRPI0406484A (pt) * | 2003-01-17 | 2005-12-06 | Vital Health Sciences Pty Ltd | Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| US8252322B2 (en) * | 2003-06-03 | 2012-08-28 | Corn Products Development, Inc. | Delivery system with increased bioavailability |
| TW200524541A (en) * | 2003-11-17 | 2005-08-01 | Cargill Inc | Lecithin-containing granular compositions and methods of their preparation |
| US20060069157A1 (en) * | 2004-02-19 | 2006-03-30 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy |
| CA2557354C (en) | 2004-03-03 | 2013-05-07 | Vital Health Sciences Pty Ltd. | Alkaloid formulations |
| RU2448977C2 (ru) * | 2004-09-16 | 2012-04-27 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью |
| US7901675B2 (en) * | 2004-10-13 | 2011-03-08 | U.S. Department Of Veterans Affairs | Method of using coenzyme Q10 to treat Huntington's disease |
| US7579319B2 (en) | 2004-12-06 | 2009-08-25 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| US20060135612A1 (en) * | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| WO2006092024A1 (en) * | 2005-03-03 | 2006-09-08 | Vital Health Sciences Pty Ltd | Compounds having anti-cancer properties |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| EP1890715A4 (en) * | 2005-04-29 | 2009-10-28 | Univ California | PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES |
| MX2007015949A (es) * | 2005-06-17 | 2008-03-07 | Vital Health Sciences Pty Ltd | Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos. |
| DE102005056558B4 (de) * | 2005-11-25 | 2009-04-30 | Gisela Susilo | Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile |
| WO2007070981A1 (en) * | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd | Compounds having cytokine modulating properties |
| GB0603975D0 (en) * | 2006-03-01 | 2006-04-05 | Etren | Methods and agents for reducing oxidative stress |
| CA2649315A1 (en) * | 2006-04-10 | 2007-10-25 | Mitsubishi Gas Chemical Company, Inc. | Brain function-improving agent, and functional food containing the improving agent |
| US20100061969A1 (en) * | 2006-11-22 | 2010-03-11 | Asahi Kasei Pharma Corporation | Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic |
| EP2195331B1 (en) | 2007-08-28 | 2013-11-20 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| JP5806287B2 (ja) | 2010-03-30 | 2015-11-10 | フォスファジェニクス リミティド | 経皮送達パッチ |
| WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
| US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| MX383940B (es) | 2015-12-09 | 2025-03-14 | Phosphagenics Ltd | Formulación farmacéutica que contiene tocol fosfato. |
| JP7198754B2 (ja) | 2016-12-21 | 2023-01-04 | アベーチョ バイオテクノロジー リミテッド | 方法 |
| US12264593B1 (en) | 2023-11-09 | 2025-04-01 | Pratt & Whitney Canada Corp. | Damped bladed rotor for gas turbine engine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2472384A1 (fr) * | 1979-12-27 | 1981-07-03 | Sederma Sa | Utilisation en cosmetologie de complexes naturels constitues d'ubiquinones et de phospholipides |
| EP0083108A2 (en) * | 1981-12-28 | 1983-07-06 | Eisai Co., Ltd. | Aqueous solution containing ubidecarenone |
| EP0094692A1 (en) * | 1982-05-19 | 1983-11-23 | Eisai Co., Ltd. | Coated ubidecarenone-containing liposome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5938202B2 (ja) * | 1976-03-05 | 1984-09-14 | エーザイ株式会社 | 難聴治療剤 |
| JPS5356315A (en) * | 1976-11-01 | 1978-05-22 | Eisai Co Ltd | Emulsified solution of fat soluble drugs |
| US4221784A (en) * | 1979-04-05 | 1980-09-09 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering lecithin |
| JPS5742616A (en) * | 1980-08-27 | 1982-03-10 | Furointo Sangyo Kk | Ubiquinone pharmaceutical having improved absorption |
| JPS5775916A (en) * | 1980-10-29 | 1982-05-12 | Nippon Chemiphar Co Ltd | Coenzyme q pharmaceutical and its preparation |
| JPS57142911A (en) * | 1981-02-28 | 1982-09-03 | Furointo Sangyo Kk | Absorption-improving agent |
| CH649917A5 (en) * | 1982-03-19 | 1985-06-28 | Italfarmaco Sa | Pharmaceutical formulations containing the coenzyme Q(10) suitable for topical administration |
-
1984
- 1984-04-09 CH CH1774/84A patent/CH661438A5/it not_active IP Right Cessation
- 1984-05-14 DE DE3417857A patent/DE3417857C2/de not_active Expired - Lifetime
-
1985
- 1985-04-01 GB GB08508452A patent/GB2157171B/en not_active Expired
- 1985-04-02 US US06/718,884 patent/US4684520A/en not_active Expired - Lifetime
- 1985-04-05 IT IT20271/85A patent/IT1201412B/it active
- 1985-04-06 JP JP7339485A patent/JPS6133118A/ja active Granted
- 1985-04-09 FR FR858505338A patent/FR2562422B1/fr not_active Expired
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2472384A1 (fr) * | 1979-12-27 | 1981-07-03 | Sederma Sa | Utilisation en cosmetologie de complexes naturels constitues d'ubiquinones et de phospholipides |
| EP0083108A2 (en) * | 1981-12-28 | 1983-07-06 | Eisai Co., Ltd. | Aqueous solution containing ubidecarenone |
| EP0094692A1 (en) * | 1982-05-19 | 1983-11-23 | Eisai Co., Ltd. | Coated ubidecarenone-containing liposome |
Non-Patent Citations (3)
| Title |
|---|
| C.A. 1982 97, 78891p * |
| C.A. 1983 98, 59920b * |
| C.A. 1985 102, 32098d * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8508452D0 (en) | 1985-05-09 |
| FR2562422B1 (fr) | 1989-03-31 |
| JPH0530813B2 (ref) | 1993-05-11 |
| JPS6133118A (ja) | 1986-02-17 |
| IT1201412B (it) | 1989-02-02 |
| DE3417857A1 (de) | 1985-10-17 |
| GB2157171B (en) | 1988-07-06 |
| US4684520A (en) | 1987-08-04 |
| GB2157171A (en) | 1985-10-23 |
| CH661438A5 (it) | 1987-07-31 |
| FR2562422A1 (fr) | 1985-10-11 |
| IT8520271A0 (it) | 1985-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3417857A1 (de) | Arzneimittel mit antianoxischer und zerebral-metabolischer wirkung | |
| DE69904208T2 (de) | Antioxidative mischung bestehend aus acetyl l-carnitin und alpha-liponsäure | |
| DE3008082C2 (ref) | ||
| DE60124240T2 (de) | Pyrophosphate zur erhöhung der zellfunktion durch schutz von muscarinrezeptoren | |
| DE69815872T2 (de) | Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch | |
| EP0359981B1 (de) | Pharmazeutische Kombinationspräparate und deren Verwendung als antineoplastische Arzneimittel | |
| DE69910560T2 (de) | Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga | |
| DE69911441T2 (de) | Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel | |
| DE60015893T2 (de) | Zusammensetzung enthaltend ein carnitine und glutathion, zur erhöhung der absorption von glutathion und zur synergisierung seiner effekte | |
| DE4430593C2 (de) | Verfahren zur Herstellung von Liposomal verkapseltem Taxol | |
| DE3537550A1 (de) | Pharmazeutische zusammensetzung | |
| DE69328618T2 (de) | Medikamente auf der Basis von Docosahexaensäure, als Plättchenaggregationshemmer und gegen cerebralen Mangel an Fettsäuren, und Verfahren zur Herstellung. | |
| DE2914788A1 (de) | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung | |
| EP1007018A2 (de) | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon | |
| DE2921852A1 (de) | Lipide senkendes mittel | |
| DE2914789C2 (ref) | ||
| DE10326822A1 (de) | Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels | |
| EP1239862B1 (de) | Pharmazeutische zubereitung enthaltend zytostatika und elektronenakzeptoren zur behandlung von krebs | |
| EP1660097A1 (de) | Physiologisch aktive zusammensetzung auf phosphatidylserin-basis | |
| DE69927701T2 (de) | Antioxidative zusammensetzung enthaltend propionyl l-carnitin und ein flavonoid gegen thrombose und atherosklerose | |
| WO2000012071A2 (de) | Pharmazeutisches und/oder diätetisches produkt | |
| EP1064002A1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| DE10148065A1 (de) | (Ester)-Lysolecithine in Liposomen | |
| DE60025215T2 (de) | L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit | |
| DE3609005A1 (de) | Pharmazeutische zusammensetzungen mit metabolischer aktivitaet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8128 | New person/name/address of the agent |
Representative=s name: WILHELMS, R., DIPL.-CHEM. DR.RER.NAT. KILIAN, H., |
|
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: F.W. WIRTZ & CO GMBH, 42781 HAAN, DE |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |